Nektar Therapeutics (NKTR) Total Current Liabilities (2010 - 2026)

Nektar Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $57.7 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 18.64% year-over-year to $57.7 million; the TTM figure through Mar 2026 stood at $57.7 million (down 18.64% YoY), while the FY2025 annual figure was $53.5 million, down 12.81% from the prior year.
• Total Current Liabilities was $57.7 million for Q1 2026 at Nektar Therapeutics, up from $53.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $105.3 million in Q1 2022 to a low of $50.7 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $66.8 million across 5 years, with a median of $61.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities slumped 51.71% in 2023, then jumped 35.35% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $68.2 million in 2022, then declined by 24.83% to $51.3 million in 2023, then increased by 19.76% to $61.4 million in 2024, then dropped by 12.81% to $53.5 million in 2025, then rose by 7.79% to $57.7 million in 2026.
• The last three Total Current Liabilities figures came in at $57.7 million (Q1 2026), $53.5 million (Q4 2025), and $66.3 million (Q3 2025), per Business Quant data.